Leaderboard

En | De
No articles selected!     View Cart  
You are here: Oncology » Urologic Neoplasms 19. November 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Zoom: Zoom In Zoom Out

   Page 1 of 9155  Previews Next
   
   Articles 1 - 20 / 183094  
   
Cancer-associated fibroblasts and extracellular matrix remodeling driving drug resistance and immune evasion in bladder cancer: research progress.
Front Immunol
Lu P, Zhou L.
PMID: 43054729 [PubMed - indexed for MEDLINE]


Closing the loop in PSMA radiopharmaceutical therapy for prostate cancer: from eligibility to decision-validated treatment.
Front Med (Lausanne)
Gambini JP.
PMID: 43054230 [PubMed]


Secondary Analysis of a Randomized Controlled Trial of Adjuvant Chemotherapy by PSA Response Following Radiotherapy.
Cancer Med
Mihalcik SA, Regan MM, Rosenthal SA, Bubley GJ, Pienta KJ, Gomella LG, Hartford AC, Michalski JM, Rajan R, McDonald AM, Dominello MM, Grignon D, Jones CU, Atkins JN, Moughan J, Sandler HM, Kaplan ID.
PMID: 43053607 [PubMed - indexed for MEDLINE]


Intelligent Prediction of WHO/ISUP Grade in Clear-Cell Renal Cell Carcinoma Using CT-Based Fusion Delta Features: A Multicenter Study with Biological Interpretability Exploration.
Acad Radiol
Wang L, Wang Z, Xu J, Li G, Xu R, Wang J, Lin F, Xi X, Kang X, Wu J, Ma H, Guo H.
PMID: 43053510 [PubMed - as supplied by publisher]


Applications of dendrimers for prostate cancer gene therapy: current status and future perspectives.
Nanomedicine (Lond)
Kasurka B, Serry Moursy E, Dufès C.
PMID: 43053339 [PubMed - as supplied by publisher]


The prognostic impact of variant histology timing in bladder cancer: a comparative analysis of primary and secondary detection.
BMC Urol
Dama M, Ahmadzada J, Efiloglu O, Bozkurt YE, Iplikci A, Nuroglu MT, Turan T, Yildirim A.
PMID: 43052964 [PubMed - indexed for MEDLINE]


Systemic immune-inflammation index, but not neutrophil-to-lymphocyte ratio, is a predictor for detecting clinically significant prostate cancer at first biopsy.
BMC Urol
Lee JW, Cho MC.
PMID: 43052936 [PubMed - indexed for MEDLINE]


Early-life recurrent antibiotic use and risks of adult kidney cancer and sex-specific cancers: a prospective cohort study in the UK Biobank.
BMC Cancer
Peng J, Wang X, Wang J, Zhu D, Sun X, Zhen X.
PMID: 43052882 [PubMed - indexed for MEDLINE]


Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Network Meta-analysis.
Target Oncol
Matsukawa A, Mori K, Yanagisawa T, Miyajima K, Enei Y, Fukuokaya W, Ito K, Tsuzuki S, Cormio A, Miszczyk M, Pradere B, Moschini M, Shariat SF, Miki J, Kimura T.
PMID: 43052561 [PubMed - as supplied by publisher]


French AFU Cancer Committee Guidelines - Update 2026-2028: Penile cancer.
Fr J Urol
Neuville P, Escoffier A, Goujon A, Rocher L, Fléchon A, Branger N, Camparo P, Levy S, Savoie PH, Murez T, Roupret M.
PMID: 43051713 [PubMed - indexed for MEDLINE]


French AFU Cancer Committee Guidelines - Update 2026-2028: Testicular germ cell cancer.
Fr J Urol
Murez T, Fléchon A, Branger N, Savoie PH, Rocher L, Camparo P, Neuville P, Escoffier A, Levy S, Goujon A, Roupret M.
PMID: 43051711 [PubMed - indexed for MEDLINE]


French AFU Cancer Committee Guidelines - Update 2026-2028: Upper urinary tract urothelial tumors (UTUC).
Fr J Urol
Roumiguié M, Leon P, Xylinas E, Thibault C, Seisen T, Prost D, Allory Y, Bajeot AS, Pradère B, Neuzillet Y, Marcq G, Audenet F, Borchiellini D, Gabriel PE, Masson-Lecomte A, Roupret M.
PMID: 43051710 [PubMed - indexed for MEDLINE]


French AFU Cancer Committee Guidelines - Update 2026-2028: Muscle-invasive bladder tumors (MIBC).
Fr J Urol
Roumiguié M, Marcq G, Bajeot AS, Allory Y, Borchiellini D, Sargos P, Leon P, Masson-Lecomte A, Neuzillet Y, Audenet F, Gabriel PE, Xylinas E, Pradère B, Prost D, Thibault C, Seisen T, Roupret M.
PMID: 43051709 [PubMed - indexed for MEDLINE]


French AFU Cancer Committee Guidelines - Update 2026-2028: Prostate cancer - Diagnosis and management of localized disease.
Fr J Urol
Ploussard G, Baboudjian M, Barret E, Brureau L, Fiard G, Fromont G, Olivier J, Dariane C, Mathieu R, Rozet F, Peyrottes A, Roubaud G, Renard-Penna R, Sargos P, Supiot S, Turpin L, Rouprêt M.
PMID: 43051708 [PubMed - indexed for MEDLINE]


French AFU Cancer Committee Guidelines - Update 2026-2028: Non-muscle-invasive bladder tumors (NMIBC).
Fr J Urol
Roumiguié M, Pradère B, Bajeot AS, Leon P, Xylinas E, Allory Y, Marcq G, Prost D, Neuzillet Y, Thibault C, Gabriel PE, Borchiellini D, Masson-Lecomte A, Seisen T, Audenet F, Roupret M.
PMID: 43051707 [PubMed - indexed for MEDLINE]


French AFU Cancer Committee Guidelines - Update 2026-2028: Kidney cancer.
Fr J Urol
Bigot P, Khene ZE, Margue G, Albiges L, Barthelemy P, Bernhard JC, Correas JM, De Vergie S, Doumerc N, Ferragu M, Ingels A, Ouzaïd I, Pettenati C, Rioux-Leclercq N, Chapet O, Waeckel T, Boissier R, Rourpret M.
PMID: 43051705 [PubMed - indexed for MEDLINE]


French AFU Cancer Committee Guidelines - Update 2026-2028: Prostate Cancer - Treatment of relapse and metastatic disease.
Fr J Urol
Ploussard G, Dariane C, Mathieu R, Baboudjian M, Barret E, Brureau L, Fiard G, Fromont G, Olivier J, Rozet F, Peyrottes A, Renard-Penna R, Sargos P, Supiot S, Turpin L, Roubaud G, Rouprêt M, Cancer Committee of the French Association of Urology.
PMID: 43051704 [PubMed - indexed for MEDLINE]


Single- Versus Two-Fraction HDR Brachytherapy Boost for Prostate Cancer: Long-Term Oncologic and Toxicity Outcomes.
Pract Radiat Oncol
Goñi A, Sevilla M, Larruskain M, Eguiguren M, Perez A, de Urturi ES, Iceta U, Roura DA, Alberich M, Minguez J, Urraca JM, Querejeta A.
PMID: 43051583 [PubMed - as supplied by publisher]


Homologous recombination repair gene alterations in prostate cancer: expert recommendations for genetic and biomarker testing.
Curr Opin Urol
Shariat SF, Morgan TM, Wyatt AW, Mehra N, Lang J, Briers E, Liang S, Grimm MO.
PMID: 43050498 [PubMed - as supplied by publisher]


Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials.
PLoS Comput Biol
Italia M, Bordel-Vozmediano S, García Otero J, Calvo GF, Pérez-García VM.
PMID: 43050486 [PubMed - as supplied by publisher]


   
   Articles 1 - 20 / 183094    Page 1 of 9155  Previews Next

 
Rect Bottom
Adserver Footer
 

  Time frame  
   

Sky right 1